MERS-CoV vaccines candidates in development: The current landscape.

Author Information (click to view)

Modjarrad K,

Modjarrad K, (click to view)

Modjarrad K,

Share on FacebookTweet about this on TwitterShare on LinkedIn

Vaccine 2016 4 12() pii 10.1016/j.vaccine.2016.03.104


Middle East respiratory syndrome coronavirus (MERS-CoV), an emerging infectious disease of growing global importance, has caused severe acute respiratory disease in more than 1600 people, resulting in almost 600 deaths. The high case fatality rate, growing geographic distribution and vaguely defined epidemiology of MERS-CoV have created an urgent need for effective public health countermeasures, paramount of which is an effective means of prevention through a vaccine or antibody prophylaxis. Despite the relatively few number of cases to-date, research and development of MERS-CoV vaccine candidates is advancing quickly. This review surveys the landscape of these efforts across multiple groups in academia, government and industry.

Submit a Comment

Your email address will not be published. Required fields are marked *

9 + 13 =